Abstract
IL-10-producing regulatory B cells have been undoubtedly identified in mice and shown to downregulate inflammation, making them potentially important for maintenance of tolerance. Several recent works have also identified IL-10 producing regulatory B cells in humans and have begun to unravel their phenotype and mode of suppression. Cell surface phenotype of human Bregs includes CD38, CD27, CD24 and CD5. Mechanisms of suppression may imply inhibition of CD4+ T proliferation, inhibition of Th1 differentiation, induction of regulatory T cells and suppression of monocytes activation. These recent findings imply that manipulating IL-10 production by human B cells could be a useful therapeutic strategy for modulating immune responses in humans.
Keywords: B cell, interleukin 10, tolerance.
Current Molecular Medicine
Title:IL-10 Producing Regulatory B Cells in Mice and Humans: State of the Art
Volume: 12 Issue: 5
Author(s): J. -D. Bouaziz, H. Le Buanec, A. Saussine, A. Bensussan and M. Bagot
Affiliation:
Keywords: B cell, interleukin 10, tolerance.
Abstract: IL-10-producing regulatory B cells have been undoubtedly identified in mice and shown to downregulate inflammation, making them potentially important for maintenance of tolerance. Several recent works have also identified IL-10 producing regulatory B cells in humans and have begun to unravel their phenotype and mode of suppression. Cell surface phenotype of human Bregs includes CD38, CD27, CD24 and CD5. Mechanisms of suppression may imply inhibition of CD4+ T proliferation, inhibition of Th1 differentiation, induction of regulatory T cells and suppression of monocytes activation. These recent findings imply that manipulating IL-10 production by human B cells could be a useful therapeutic strategy for modulating immune responses in humans.
Export Options
About this article
Cite this article as:
-D. Bouaziz J., Le Buanec H., Saussine A., Bensussan A. and Bagot M., IL-10 Producing Regulatory B Cells in Mice and Humans: State of the Art, Current Molecular Medicine 2012; 12 (5) . https://dx.doi.org/10.2174/156652412800620057
DOI https://dx.doi.org/10.2174/156652412800620057 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Research on Opioid Receptor Function
Current Drug Targets Editorial [Hot Topic:Controlling Autoimmunity by Modulating the Function of Autoantigen-Specific T Cells (Guest Editor: Andrew D. Weinberg)]
Current Drug Targets - Inflammation & Allergy Disorders of Consciousness and Electrophysiological Treatment Strategies: A Review of the Literature and New Perspectives
Current Pharmaceutical Design Progress in Multiple Sclerosis Genetics
Current Genomics Telomere Length Variations in Aging and Age-Related Diseases
Current Aging Science Potential of Flavonoids as Anti-inflammatory Agents: Modulation of Pro- Inflammatory Gene Expression and Signal Transduction Pathways
Current Drug Metabolism Efficient Expression and Purification of Recombinant Therapeutic Protein Candidates, Human Midkine and Pleiotrophin
Current Pharmaceutical Biotechnology New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Therapeutic Peptide Mimetics Looking for a Turn to Block Aberrant Players of Malignancy
Current Cancer Therapy Reviews Tuning Immune Suppression in Systemic Autoimmunity with Self-Derived Peptides
Inflammation & Allergy - Drug Targets (Discontinued) Exploiting Microglial Functions for the Treatment of Glioblastoma
Current Cancer Drug Targets Vitamin D and the Adaptive Immune System with Special Emphasis to Allergic Reactions and Allograft Rejection
Inflammation & Allergy - Drug Targets (Discontinued) Cholinergic System and Neuroinflammation: Implication in Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry Gastrointestinal Immune System and Brain Dialogue Implicated in Neuroinflammatory and Neurodegenerative Diseases
Current Molecular Medicine The Emerging Role of the Cannabinoid Receptor Family in Peripheral and Neuro-immune Interactions
Current Drug Targets The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases
Current Neuropharmacology Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design The Role of Regulatory T Cells in Contact Hypersensitivity
Recent Patents on Inflammation & Allergy Drug Discovery Targeting Interleukin-21 in Immune-Mediated Pathologies
Current Drug Targets